Revenue: 606,176 for Q4 2024, up 34.26% QoQ from 451,509 in Q3 2024; YoY revenue growth 20,105.87% (Q4 2023 revenue was 3,000).
Gross Profit: 393,745; gross margin 64.96% (margin up vs prior periods; YoY +14.91%, QoQ +404.56%).
Operating Income: 202,356; operating margin 33.38% (YoY +278.47%, QoQ +879.79%).
EBITDA: 300,848; EBITDA margin 49.63% (EBITDA/Revenue).
Net Income: 285,851; net margin 47.16% (YoY +158.34%, QoQ -89.63%).
Earnings Per Share: not reported in the data; implied EPS is attenuated by very high diluted share count (approx. 14.69 billion weighted average shares).
Cash Flow: Operating cash flow 101,186; capex 4; free cash flow 101,190; cash at end of period 115,747; net change in cash -28,828.
Balance Sheet Health: Total assets 8,362,682; total liabilities 6,830,211; cash and cash equivalents 115,747; short-term debt 503,269; long-term debt 0; goodwill 7,685,636; retained earnings negative $(166,666,296); total stockholders’ equity approximately $(1,532,471).
Liquidity & Leverage: current ratio 0.077 (as reported); quick ratio modestly better but still well under 1; interest coverage ~18.9x driven by EBITDA vs interest expense of 10,721; debt-to-assets ~0.82; debt-to-equity ~4.46, signaling debt load concentrated in short-term obligations relative to a weak equity base.
Valuation: price-to-book 2.88x; price-to-sales 7.27x; price-to-earnings ~3.85x; enterprise value multiple ~15.94x; price-to-free cash flows and other multiples imply modest to rich valuation given the liquidity risk and regulatory exposure in the CBD-based business model.